Palivizumab for the Prophylaxis of Respiratory Syncytial Virus Disease: Expert Opinion and Recommendations for the Gulf Cooperation Council Region. [PDF]
Oman Med JRespiratory syncytial virus (RSV) infection poses a significant health threat to infants and young children. Considering the substantial burden in Gulf Cooperation Council (GCC) countries, prevention of RSV remains a major public health priority ...
Alharbi AS +7 more
europepmc +2 more sources
Infecções respiratórias em crianças menores de dois anos de idade submetidas a profilaxia com palivizumabe [PDF]
, 2014 OBJECTIVE: To identify the viruses involved in acute respiratory tract infections and to analyze the rates of hospitalization and death in children on palivizumab prophylaxis.METHODS:Prospective cohort of 198 infants up to one year old who were born ...
Bellei, Nancy Cristina Junqueira +4 more
core +3 more sources
Palivizumab for preterm infants. Is it worth it? [PDF]
Archives of Disease in Childhood - Fetal and Neonatal Edition, 2005 Respiratory syncytial virus infection is an important cause of morbidity. Although palivizumab prophylaxis is widely used, it is uncertain whether the cost is justified. A systematic review was therefore performed of the safety, efficacy, and the likely cost effectiveness of prophylaxis for preterm infants in the United Kingdom using a standard search ...
Nicholas D. Embleton +2 more
openaire +3 more sources
A cost-effectiveness analysis of respiratory syncytial virus (RSV) prophylaxis in infants in the United Kingdom / [PDF]
, 2013 Background: Respiratory syncytial virus (RSV) is a common cause of respiratory infection that is highly prevalent in infants. Severe cases of RSV infection require hospitalisation; this is most likely to occur in infant populations at high risk.
Bentley, Anthony +3 more
core +1 more source
Respiratory related hospitalizations in premature infants prophylaxed with palivizumab In the Canadian registry of palivizumab (CARESS) [PDF]
7.6 Paediatric Respiratory Epidemiology, 2015 Background: Efficacy and safety of palivizumab for respiratory syncytial virus (RSV) prophylaxis in infants ≤35 weeks gestational age (WGA), shown by randomized trial. Data limited on incidence of hospitalization for respiratory related events in prophylaxed infants in the lower GA groups.
Bosco Paes +4 more
openaire +3 more sources
Few and Far Between: How HIV May Be Evading Antibody Avidity [PDF]
, 2010 No ...
Bjorkman, Pamela J., Klein, Joshua S.
core +3 more sources
Palivizumab and RSV prevention [PDF]
Archives of Disease in Childhood, 2000 Editor,—The letters from Drs Deshpande and Nicholl, in relation to the Impact-RSV study and the UK guidance for the use of palivizumab in the prevention of serious RSV infections, raise interesting questions that need to be addressed. I believe Dr Deshpande “has got it wrong” in that he fails to realise that the primary objective of the IMpact study ...
openaire +1 more source
Respiratory syncytial virus: diagnosis, prevention and management. [PDF]
, 2019 Respiratory syncytial virus (RSV) is responsible for a large burden of disease globally and can present as a variety of clinical syndromes in children of all ages.
British Thoracic Society +14 more
core +1 more source
Molecular Evolution of Respiratory Syncytial Virus Fusion Gene, Canada, 2006–2010
Emerging Infectious Diseases, 2012 To assess molecular evolution of the respiratory syncytial virus (RSV) fusion gene, we analyzed RSV-positive specimens from 123 children in Canada who did or did not receive RSV immunoprophylaxis (palivizumab) during 2006–2010.
Jesse Papenburg +11 more
doaj +1 more source
BMC Infectious Diseases, 2017 Background This study aimed at estimating the efficiency of palivizumab in the prevention of Respiratory Syncytial Virus (RSV) infection and its sequelae in preterm infants (32day 1-35day 0weeks of gestational age –wGA-) in Spain. Methods A decision-tree
M. Sanchez-Luna +6 more
doaj +1 more source